Paper Details

  1. Home
  2. Paper Details

[Renal cell carcinoma and antiangiogenic therapies].

Author: CulineStéphane, PatardJean-Jacques, PouesselDamien, VerhoestGregory

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Targeted therapies such as sunitinib, sorafenib, bevacizumab, and temsirolimus have shown promise in treating metastatic renal cell carcinoma (RCC), offering improved progression-free survival and overall survival compared to traditional immunotherapy.
Paper Details　
Original Abstract of the Article :
Until 2006, immunotherapy (interferon-alpha or interleukin 2) was the standard medical treatment for metastatic renal cell carcinoma (RCC), and its results were disappointing: despite a few cases of complete response with prolonged survival, median survival was one year. Better understanding of the ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.lpm.2007.07.007

データ提供：米国国立医学図書館（NLM）

Renal Cell Carcinoma: A New Era of Targeted Therapies

Renal cell carcinoma (RCC), a challenging form of cancer, has seen significant advancements in treatment strategies over the past decade. This research explores the emergence of antiangiogenic therapies, a novel approach that targets the growth of blood vessels that nourish tumors. The authors provide a comprehensive overview of the latest antiangiogenic therapies, including sunitinib, sorafenib, bevacizumab, and temsirolimus, highlighting their potential benefits and limitations in the treatment of metastatic RCC.

Antiangiogenic Therapies: A Revolution in Renal Cell Carcinoma Treatment

This research highlights the transformative impact of antiangiogenic therapies in the treatment of metastatic renal cell carcinoma (RCC). The authors discuss the mechanisms of action of various antiangiogenic agents, emphasizing their ability to inhibit the growth of blood vessels that supply tumors. Their findings provide a glimpse into the future of RCC treatment, suggesting that targeted therapies may offer a more effective and personalized approach.

A New Frontier in Cancer Treatment: The Promise of Antiangiogenic Therapies

Imagine a desert oasis, where a spring of water sustains life. This research explores the potential of antiangiogenic therapies to similarly starve tumors by cutting off their blood supply. The authors' insights into the mechanisms of action of these therapies offer a promising outlook for the future of RCC treatment, suggesting that targeted approaches may offer a more effective and personalized path towards recovery.

Dr.Camel's Conclusion

This research provides a comprehensive overview of the latest advancements in antiangiogenic therapies for the treatment of metastatic renal cell carcinoma (RCC). The authors discuss the mechanisms of action, potential benefits, and limitations of these therapies, offering valuable insights for clinicians and patients alike.
Date :
  1. Date Completed 2008-06-03
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

18035517

DOI: Digital Object Identifier

10.1016/j.lpm.2007.07.007

Related Literature

Article Analysis
・Side Effects of temsirolimus
SNS
PICO Info
in preparation
Languages

French

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.